ReviewClinical microbiology reviews2020
Convalescent Plasma Therapy for COVID-19: State of the Art.
Review in Clinical microbiology reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 74 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Trial of Convalescent Plasma Administration as Adjunct Therapy for COVID-19 (Uji Klinik Pemberian Plasma Konvalesen Sebagai Terapi Tambahan COVID-19)
Effectiveness of Convalescent Plasma Therapy in 8 Non-Intubated COVID-19 Patients in Indonesia: A Case Series
Who cites it
74 citing papers in PubMed, 4 syntheses or guidelines pooled it, 132 citations in OpenAlex.
- Convalescent plasma and all-cause mortality of COVID-19 patients: systematic review and meta-analysis.Scientific reports · 2023Pooled it
- Pooled it
- Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.JMIR public health and surveillance · 2021Pooled it
- Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis.F1000Research · 2021Pooled it
- Emerging Vector-Borne Nipah Virus Infection: Unexplored Hazards, Diagnostic Challenges, and the Potential of Phytomedicine-Based Therapeutics.Current pharmaceutical design · 2026Review
- How does the Immunological System Change during the SARS-COV-2 Attack? A Clue for the New Immunotherapy Discovery.Current medicinal chemistry · 2025Review
- Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control.Signal transduction and targeted therapy · 2024Review
- Efficacy and Safety of Treatment with Plasma from COVID-19-Recovered Individuals.Life (Basel, Switzerland) · 2023Article
- Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era.Experimental hematology & oncology · 2023Review
- Plasma cell-free DNA promise monitoring and tissue injury assessment of COVID-19.Molecular genetics and genomics : MGG · 2023Article
- Drug target of natural products and COVID-19: how far has science progressed?Annals of medicine and surgery (2012) · 2023Article
- Therapeutics for COVID-19.Nature microbiology · 2023Review
- Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update.Process biochemistry (Barking, London, England) · 2023Review
- Exploring m6A-RNA methylation as a potential therapeutic strategy for acute lung injury and acute respiratory distress syndrome.Pulmonary circulation · 2023Review
- Correlation of SARS-CoV-2 Neutralization with Antibody Levels in Vaccinated Individuals.Viruses · 2023Article
- PEGylation Prolongs the Half-Life of Equine Anti-SARS-CoV-2 Specific F(ab')International journal of molecular sciences · 2023Article
- Extracellular vesicles mediate antibody-resistant transmission of SARS-CoV-2.Cell discovery · 2023Article
- Factors influencing plasma donation behavior of COVID-19 recovered patients in Bangladesh: A pilot study.Health science reports · 2023Article
- An update on SARS-CoV-2 immunization and future directions.Frontiers in pharmacology · 2023Review
- Efficacy of COVID-HIGIV in animal models of SARS-CoV-2 infection.Scientific reports · 2022Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Convalescent plasma (CP) therapy has been used since the early 1900s to treat emerging infectious diseases; its efficacy was later associated with the evidence that polyclonal neutralizing antibodies can reduce the duration of viremia. Recent large outbreaks of viral diseases for which effective antivirals or vaccines are still lacking has renewed the interest in CP as a life-saving treatment. The ongoing COVID-19 pandemic has led to the scaling up of CP therapy to unprecedented levels. Compared with historical usage, pathogen reduction technologies have now added an extra layer of safety to the use of CP, and new manufacturing approaches are being explored. This review summarizes historical settings of application, with a focus on betacoronaviruses, and surveys current approaches for donor selection and CP collection, pooling technologies, pathogen inactivation systems, and banking of CP. We additionally list the ongoing registered clinical trials for CP throughout the world and discuss the trial results published thus far.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.